

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance

Roberta Castriconi¹, Alessandra Dondero², Fabio Pastorino³, Mariella Della Chiesa², Maria Valeria Corrias⁴, Fabio Morandi⁴, Vito Pistoia³, Daniel Olive⁵, Francesca Bellora², Franco Locatelli⁶, Aurora Castellano⁶, Lorenzo Moretta⁷, Cristina Bottino⁸, Alessandro Moretta¹

¹ DIMES, Scuola di Scienze Mediche e Farmaceutiche/CEBR, Università degli Studi di Genova, Genova, Italy - ² DIMES, Scuola di Scienze Mediche e Farmaceutiche, Università degli Studi di Genova, Genova, Italy - ³ Laboratorio di Oncologia, Istituto Giannina Gaslini, Genova, Italy - ⁴ Laboratorio di Oncologia, Istituto Giannina Gaslini, Genova, Italy - ⁵ Inserm/ Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France - ⁶ Università di Pavia /Dipartimento di Onco-Ematologia Pediatrica, Ospedale Bambino Gesù, Roma, Italy - ⁷ Direzione scientifica, Istituto Giannina Gaslini, Genova, Italy - ⁸ DIMES, Scuola di Scienze Mediche e Farmaceutiche /CEBR, Università degli Studi di Genova, Genova/Istituto Giannina Gaslini, Genova, Italy

Neuroblastomas (NB) are neuroectodermal tumors that account for 15% of all childhood cancer deaths. Different prognostic factors including age, stage and amplification of *MYCN* (*MYCN^{amp}*), are critical for defining NB risk and for guiding therapeutic choices¹. In this context, although different strategies have been approached, the prognosis of high-risk neuroblastoma (NB) remains poor due to the high frequency of relapse which not only occurs at the primary tumor site but frequently arises in the bone marrow. Thus, in vivo, neuroblastoma exploits different mechanisms to escape the immune surveillance². These might include the so called “adaptive immune resistance” characterized by the *de-novo* expression of Programmed Death Ligands (PD-Ls)³ induced by IFN- γ whose storm occurs after different immunotherapeutic approaches. In the present study we analyzed the constitutive and the inducible surface expression of PD-Ls in NB cells. We showed that PD-L1 is constitutively expressed by virtually all HLA class I^{pos} NB cell lines, whereas PD-L2 is rarely detected. Moreover PD-L1 could be acquired/upregulated in both NB cell lines and NB engrafted nude/nude mice. Importantly, after IFN- γ stimulation, PD-L1 can be expressed by metastatic neuroblasts isolated from bone marrow aspirates of high-risk NB patients, characterized by different *MYCN* amplification status. Interestingly, in one case, metastatic neuroblasts were poorly responsive to IFN- γ stimulation, suggesting that responsiveness to IFN- γ might represent a further element of heterogeneity in metastatic neuroblasts. Finally, we documented the presence of PD-1-positive lymphocytes in NB-infiltrated bone marrow of patients. These cells are mainly represented by $\alpha\beta$ T cells but also include small populations of $\gamma\delta$ T cells and NK cells. Moreover, PD-1^{pos} T cells expressed higher levels of activation markers as compared to the negative counterpart. Overall our data show that a PD-L1-mediated immune resistance mechanism might occur in metastatic neuroblasts and provide a biological rationale for blocking the PD-1/PD-Ls axis in future combined immunotherapeutic approaches.

This work was supported by Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) (Investigator Grant 15704 and special project 5x1000 9962), Ministero dell’Istruzione, dell’Università e della Ricerca (M.I.U.R.) (PRIN 20103FMJEN) and Ministero della Salute (5 x 1000 e Ricerca Corrente) and Equipe FRM DEQ20140329534.

References

1. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009; 27:289-97.
2. Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, et al. Natural Killer Cells and Neuroblastoma: tumor recognition, escape mechanisms and possible novel immunotherapeutic approaches. *Front Immunol* (in press) 2014.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nature reviews Cancer* 2012; 12:252-64.

Keywords

Anti-tumor immunity; Immune checkpoints; Neuroblastoma; Natural Killer cells; T cells; PD-1; PD-L1; PD-L2; INF- γ TNF- α .